Epoch Biodesign Hired Operations Chief for Scaling
The synthetic biology firm tapped a veteran manufacturer to lead supply chain efforts as it nears commercialization.
Updated on Oct. 12, 2026 in People
Epoch Biodesign has appointed Jamie Scott as Chief Operating Officer to oversee production and supply chain management. The firm is currently scaling its operations, which include the acquisition of a nylon 6,6 polymerization facility in Spain and the development of a demonstration plant in London.
Why it matters
The hire signals a transition toward full-scale industrial output as the company moves to convert post-consumer waste into commercial polymers. Scott brings 30 years of experience in chemical manufacturing to oversee these complex facility integrations.
Jamie Scott joins with 30 years of industry experience to manage a 52,000-tonne-per-year polymerization facility. This Blanes, Spain site represents 10% of Europe's total nylon 6,6 production capacity.
The players
Jamie Scott
A veteran with 30 years of experience in chemical manufacturing and industrial operations appointed as Chief Operating Officer.
Jacob Nathan
Founder and CEO of Epoch Biodesign who oversees the firm's strategic push toward commercializing industrial synthetic biology.
Epoch Biodesign
A synthetic biology company focused on developing technology to process and produce chemical polymers.
The details
Scott will focus on optimizing production and supply chain logistics as the company integrates its recent facility acquisitions. This includes managing the upcoming restart of the Blanes plant and the ongoing work at the Grapht Works demonstration facility in London, which uses specialized processes to handle post-consumer nylon 6,6 waste.
Timeline
Earlier this year: Epoch Biodesign began construction of its London demonstration facility.
October 2026: Production at the Blanes facility is scheduled to restart.
Market Landscape
Epoch's appointment of an operations-heavy executive marks a common pivot point where early-stage research firms transition to managing high-volume industrial infrastructure. This aligns with a broader trend of biotech companies acquiring and repurposing existing chemical manufacturing assets.
Operators in the chemical and materials supply chain should monitor how Epoch manages the integration of these acquired assets to ensure stable throughput. The restart of the Blanes facility could shift local capacity benchmarks for nylon 6,6 in Europe by the end of the year.
The takeaway
Bringing in long-tenured manufacturing talent is often the necessary catalyst for startups attempting to bridge the gap between pilot-scale demonstration and full-scale industrial production. Track the success of the Blanes facility restart as a key indicator of the firm's commercial viability.
What happens next
Production at the Blanes facility is expected to restart later in October 2026.
Further reading
For more on shifts in corporate leadership and organizational strategy, explore People.
